Sign In
Buy CLNN
$5.76
-0.110 (-1.87%)
At Close: Jun 03, 2026
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
10:00am, Thursday, 05'th Oct 2023
Funding to Support Research and Expanded Access of Investigational Drug in ALS Funding to Support Research and Expanded Access of Investigational Drug in ALS
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
08:00am, Thursday, 28'th Sep 2023
Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
04:00pm, Monday, 25'th Sep 2023
SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage b
SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine, Inc. (collectively “Clene”), today announced long-term follow-u
Clene to Present at Upcoming September Conferences
08:20am, Wednesday, 30'th Aug 2023
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bi
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
07:00am, Wednesday, 02'nd Aug 2023
SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar
10 Top Penny Stocks To Watch Right Now For Under $1
01:20pm, Thursday, 29'th Jun 2023
Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
07:01pm, Friday, 12'th May 2023
Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago.
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
09:58am, Monday, 13'th Mar 2023
Clene Inc. (CLNN) delivered earnings and revenue surprises of -6.67% and 73.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
04:10pm, Wednesday, 08'th Mar 2023
Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9
How to Analyze Penny Stocks for Profits
06:00am, Tuesday, 14'th Feb 2023
Use these tips for analyzing penny stocks in 2023 The post How to Analyze Penny Stocks for Profits appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Clene Inc. (CLNN) Reports Q3 Loss, Tops Revenue Estimates
11:32am, Monday, 07'th Nov 2022
Clene Inc. (CLNN) delivered earnings and revenue surprises of 39.13% and 228.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Vicinity Motor Is Trading Higher By Over 65%; Here Are 26 Stocks Moving Premarket
10:54am, Wednesday, 05'th Oct 2022 Benzinga
Gainers
Vicinity Motor Corp. (NASDAQ: VEV) rose 65.4% to $1.72 in pre-market trading. Vicinity Motor started deliveries of the first Class 3 electric truck to roll off the assembly line in Canada.
SH
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022
02:30pm, Tuesday, 04'th Oct 2022 Benzinga
Upgrades
For Bank of New York Mellon Corp (NYSE:BK), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, Bank of New York Mellon had an EPS of $1.03, compared to year-ago
Domino's Pizza To $385? Plus This Analyst Cuts Price Target On Adaptimmune Therapeutics By Around 79%
02:01pm, Tuesday, 04'th Oct 2022 Benzinga
UBS cut the price target on Domino's Pizza, Inc. (NYSE: DPZ) from $430 to $385. Domino's shares rose 4% to $329.11 on Tuesday.
Raymond James boosted the price target for The Progressive Corporation
